MX2015001657A - Compuestos de cianopirazol substituidos con receptores de acido lisofosfatidico (lpar). - Google Patents

Compuestos de cianopirazol substituidos con receptores de acido lisofosfatidico (lpar).

Info

Publication number
MX2015001657A
MX2015001657A MX2015001657A MX2015001657A MX2015001657A MX 2015001657 A MX2015001657 A MX 2015001657A MX 2015001657 A MX2015001657 A MX 2015001657A MX 2015001657 A MX2015001657 A MX 2015001657A MX 2015001657 A MX2015001657 A MX 2015001657A
Authority
MX
Mexico
Prior art keywords
lpar
substituted
compounds
cyanopyrazole
cyanopyrazole compounds
Prior art date
Application number
MX2015001657A
Other languages
English (en)
Inventor
Yimin Qian
Achyutharao Sidduri
Ryan Craig Schoenfeld
David Budd
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2015001657A publication Critical patent/MX2015001657A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

La invención proporciona compuestos de la fórmula (I), así como las sales de los mismos farmacéuticamente aceptables, en donde los substituyentes son como aquellos descritos en la descripción. Estos compuestos, y las composiciones farmacéuticas que los contienen, son útiles para el tratamiento de las enfermedades y trastornos inflamatorios tales como la fibrosis pulmonar.
MX2015001657A 2012-09-05 2013-09-02 Compuestos de cianopirazol substituidos con receptores de acido lisofosfatidico (lpar). MX2015001657A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261696862P 2012-09-05 2012-09-05
PCT/EP2013/068083 WO2014037303A1 (en) 2012-09-05 2013-09-02 Lpar - substituted cyanopyrazole compounds

Publications (1)

Publication Number Publication Date
MX2015001657A true MX2015001657A (es) 2015-04-08

Family

ID=49085036

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015001657A MX2015001657A (es) 2012-09-05 2013-09-02 Compuestos de cianopirazol substituidos con receptores de acido lisofosfatidico (lpar).

Country Status (11)

Country Link
US (1) US9169215B2 (es)
EP (1) EP2892882A1 (es)
JP (1) JP2015527378A (es)
KR (1) KR20150039835A (es)
CN (1) CN104507914A (es)
BR (1) BR112015003998A2 (es)
CA (1) CA2877184A1 (es)
HK (1) HK1206356A1 (es)
MX (1) MX2015001657A (es)
RU (1) RU2015110006A (es)
WO (1) WO2014037303A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3158743A1 (en) 2019-11-15 2021-05-20 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof
AU2021282986B2 (en) 2020-06-03 2024-03-07 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
TW202344504A (zh) 2020-06-03 2023-11-16 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
US11939318B2 (en) 2021-12-08 2024-03-26 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002023986A1 (fr) * 2000-08-25 2002-03-28 Sankyo Company, Limited Derives de 4-acylaminopyrazole
EP1513522A2 (en) * 2002-01-18 2005-03-16 Sri International Methods of treating conditions associated with an edg receptor
PE20140879A1 (es) * 2010-12-07 2014-08-06 Amira Pharmaceuticals Inc Antagonistas del receptor de acido lisofosfatidico para el tratamiento de fibrosis

Also Published As

Publication number Publication date
CN104507914A (zh) 2015-04-08
BR112015003998A2 (pt) 2017-07-04
HK1206356A1 (en) 2016-01-08
KR20150039835A (ko) 2015-04-13
JP2015527378A (ja) 2015-09-17
EP2892882A1 (en) 2015-07-15
RU2015110006A (ru) 2016-10-27
CA2877184A1 (en) 2014-03-13
WO2014037303A1 (en) 2014-03-13
US20150218106A1 (en) 2015-08-06
US9169215B2 (en) 2015-10-27

Similar Documents

Publication Publication Date Title
IN2014DN09352A (es)
IN2014DN09348A (es)
IN2014DN09347A (es)
PH12016500024A1 (en) Bromodomain inhibitor
WO2014179564A8 (en) Thiazolopyrrolidine inhibitors of ror-gamma
IN2014DN09434A (es)
MX2014000341A (es) Novedosos derivados de trifluoro-metil-oxadiazol y su uso en el tratamiento de enfermedades.
IN2014MN02598A (es)
IN2015DN01119A (es)
MX2014012695A (es) Derivados de isoindolona.
PH12014501542B1 (en) Substituted pyrrolidine -2- carboxamides
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
MX2016002794A (es) Compuestos antiproliferativos.
PH12014501967B1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
WO2014045162A8 (en) ALKYL-SUBSTITUTED HEXAHYDROPYRANO[3,4-d] [1,3]THIAZIN-2-AMINE COMPOUNDS
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
IN2014DN06869A (es)
MX340574B (es) Imidazo pirazinas.
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
MX2017004852A (es) Inhibidores de aldosterona sintasa.
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
TN2017000342A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones
WO2015002755A3 (en) Compounds for the treatment of malaria
MX2015001657A (es) Compuestos de cianopirazol substituidos con receptores de acido lisofosfatidico (lpar).
MX2013003202A (es) Inhibidores de oxadiazol de la produccion de leucotrienos.